{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:57:32Z","timestamp":1793923052788,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00213-018-5133-z","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T08:56:00Z","timestamp":1543568160000},"page":"545-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis"],"prefix":"10.1007","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4933-4162","authenticated-orcid":false,"given":"Robert C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"5133_CR1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","volume":"72","author":"O Agid","year":"2011","unstructured":"Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G (2011) An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 72:1439\u20131444","journal-title":"J Clin Psychiatry"},{"key":"5133_CR2","doi-asserted-by":"crossref","unstructured":"Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD (2005) Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol (Oxford, England) 19:110\u2013117","DOI":"10.1177\/0269881105058978"},{"key":"5133_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"Asssociation AD, Association AP","year":"2004","unstructured":"Asssociation AD, Association AP (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596\u2013601","journal-title":"Diabetes Care"},{"key":"5133_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges L, Higgins J, Rothstein H (2009) Introduction to meta-analysis. Wiley, West Sussex"},{"key":"5133_CR5","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU (2017) Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 78:e264\u2013e278","journal-title":"J Clin Psychiatry"},{"key":"5133_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159:130\u2013137","journal-title":"Ann Intern Med"},{"key":"5133_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","volume":"55","author":"L Citrome","year":"2004","unstructured":"Citrome L, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv (Washington, DC) 55:1006\u20131013","journal-title":"Psychiatr Serv (Washington, DC)"},{"key":"5133_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","volume":"174","author":"CU Correll","year":"2016","unstructured":"Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM (2016) Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 174:82\u201392","journal-title":"Schizophr Res"},{"key":"5133_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","volume":"74","author":"CU Correll","year":"2017","unstructured":"Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S (2017) Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74:675\u2013684","journal-title":"JAMA Psychiatry"},{"key":"5133_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","volume":"22","author":"P Czobor","year":"2002","unstructured":"Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA (2002) Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 22:244\u2013251","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"5133_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","volume":"174","author":"M Davidson","year":"2017","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J, Weiser M, Luthringer R (2017) Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry 174(12):1195\u20131202 appiajp201717010122","journal-title":"Am J Psychiatry"},{"key":"5133_CR12","doi-asserted-by":"publisher","first-page":"2s","DOI":"10.1097\/00004714-198602001-00002","volume":"6","author":"JM Davis","year":"1986","unstructured":"Davis JM, Andriukaitis S (1986) The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 6:2s\u201310s","journal-title":"J Clin Psychopharmacol"},{"key":"5133_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","volume":"24","author":"JM Davis","year":"2004","unstructured":"Davis JM, Chen N (2004) Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24:192\u2013208","journal-title":"J Clin Psychopharmacol"},{"key":"5133_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/schbul\/6.1.70","volume":"6","author":"JM Davis","year":"1980","unstructured":"Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70\u201387","journal-title":"Schizophr Bull"},{"key":"5133_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","volume":"47","author":"JM Davis","year":"1994","unstructured":"Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47:741\u2013773","journal-title":"Drugs"},{"key":"5133_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","volume":"70","author":"G Desamericq","year":"2014","unstructured":"Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, Maison P (2014) Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 70:127\u2013134","journal-title":"Eur J Clin Pharmacol"},{"key":"5133_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3371\/CSRP.5.2.3","volume":"5","author":"R Ganguli","year":"2011","unstructured":"Ganguli R, Brar JS, Garbut R, Chang CC, Basu R (2011) Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 5:75\u201379","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"5133_CR18","first-page":"77","volume":"23","author":"G Guilera","year":"2009","unstructured":"Guilera G, Pino O, Gomex-Benito J, Rojo J (2009) Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomized controlled trials. Eur J Psychatr 23:77\u201389","journal-title":"Eur J Psychatr"},{"key":"5133_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","volume":"173","author":"B Helfer","year":"2016","unstructured":"Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, Engel RR, Leucht S (2016) Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173:876\u2013886","journal-title":"Am J Psychiatry"},{"key":"5133_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","volume":"163","author":"S Heres","year":"2006","unstructured":"Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185\u2013194","journal-title":"Am J Psychiatry"},{"key":"5133_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00406-015-0624-y","volume":"266","author":"S Heres","year":"2016","unstructured":"Heres S, Cirjaliu DM, Dehelean L, Matei VP, Podea DM, Sima D, Stecher L, Leucht S (2016) The SWITCH study: rationale and design of the trial. Eur Arch Psychiatry Clin Neurosci 266:513\u2013521","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5133_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic review of interventions","author":"J Higgins","year":"2008","unstructured":"Higgins J, Green S (2008) Cochrane handbook for systematic review of interventions. Wiley, West Sussex"},{"key":"5133_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/wps.20522","volume":"17","author":"OH Howes","year":"2018","unstructured":"Howes OH, Kaar SJ (2018) Antipsychotic drugs: challenges and future directions. World Psychiatry 17:170\u2013171","journal-title":"World Psychiatry"},{"key":"5133_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D (2012) Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry J Ment Sci 201:481\u2013485","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"5133_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/JCP.0b013e3181e5c14c","volume":"30","author":"GK Isbister","year":"2010","unstructured":"Isbister GK, Balit CR, Macleod D, Duffull SB (2010) Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol 30:391\u2013395","journal-title":"J Clin Psychopharmacol"},{"key":"5133_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Diaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthoj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE (2018) Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 5:797\u2013807","journal-title":"Lancet Psychiatry"},{"key":"5133_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","volume":"174","author":"JM Kane","year":"2016","unstructured":"Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, UC C (2016) Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 174:93\u201398","journal-title":"Schizophr Res"},{"key":"5133_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/npp.2009.164","volume":"35","author":"BJ Kinon","year":"2010","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM (2010) Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35:581\u2013590","journal-title":"Neuropsychopharmacology"},{"key":"5133_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4088\/JCP.12r08167","volume":"74","author":"NY Kirson","year":"2013","unstructured":"Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74:568\u2013575","journal-title":"J Clin Psychiatry"},{"key":"5133_CR30","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2147\/NDT.S134340","volume":"13","author":"T Kishi","year":"2017","unstructured":"Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N (2017) Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat 13:1281\u20131302","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5133_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","volume":"74","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74:957\u2013965","journal-title":"J Clin Psychiatry"},{"key":"5133_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/schbul\/sbs150","volume":"40","author":"T Kishimoto","year":"2014","unstructured":"Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192\u2013213","journal-title":"Schizophr Bull"},{"key":"5133_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","volume":"268","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268:625\u2013639","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5133_CR34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40263-016-0382-z","volume":"30","author":"KS Lao","year":"2016","unstructured":"Lao KS, He Y, Wong IC, Besag FM, Chan EW (2016) Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs 30:1043\u20131054","journal-title":"CNS Drugs"},{"key":"5133_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152\u2013163","journal-title":"Am J Psychiatry"},{"key":"5133_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","volume":"200","author":"S Leucht","year":"2012","unstructured":"Leucht S, Hierl S, Kissling W, Dold M, Davis JM (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry J Ment Sci 200:97\u2013106","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"5133_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"5133_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/schbul\/sbu001","volume":"40","author":"S Leucht","year":"2014","unstructured":"Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40:314\u2013326","journal-title":"Schizophr Bull"},{"key":"5133_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbv019","volume":"41","author":"S Leucht","year":"2015","unstructured":"Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthoj B, Leboyer M, Leweke FM, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE (2015) The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull 41:549\u2013558","journal-title":"Schizophr Bull"},{"key":"5133_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00406-016-0715-4","volume":"266","author":"S Leucht","year":"2016","unstructured":"Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G (2016a) Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci 266:477\u2013480","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Suppl 1","key":"5133_CR41","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM (2016b) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42(Suppl 1):S90\u2013S94","journal-title":"Schizophr Bull"},{"key":"5133_CR42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174:927\u2013942","journal-title":"Am J Psychiatry"},{"key":"5133_CR43","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"J Lieberman","year":"2005","unstructured":"Lieberman J, Stroup T, MCevoy J, Swartz M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, BD L, Severe J, Hsiao J, Investigators C (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"5133_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1017\/neu.2016.57","volume":"29","author":"SR Marder","year":"2017","unstructured":"Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, Weiss C, Hobart M (2017) Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr 29:278\u2013290","journal-title":"Acta Neuropsychiatr"},{"key":"5133_CR45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","volume":"62","author":"M Marshall","year":"2005","unstructured":"Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62:975\u2013983","journal-title":"Arch Gen Psychiatry"},{"key":"5133_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/archpsyc.1976.01770040047009","volume":"33","author":"PR May","year":"1976","unstructured":"May PR, Tuma AH, Yale C, Potepan P, Dixon WJ (1976) Schizophrenia\u2014a follow-up study of results of treatment. Arch Gen Psychiatry 33:481\u2013486","journal-title":"Arch Gen Psychiatry"},{"key":"5133_CR47","doi-asserted-by":"crossref","unstructured":"McCutcheon R, Beck K, Bloomfield MA, Marques TR, Rogdaki M, Howes OD (2015) Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol (Oxford, England) 29:892\u2013897","DOI":"10.1177\/0269881115576688"},{"key":"5133_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 101:273\u2013286","journal-title":"Schizophr Res"},{"key":"5133_CR49","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","volume":"389","author":"G Nemeth","year":"2017","unstructured":"Nemeth G, Laszlovszky I, Czobor P, Szalai E, Szatmari B, Harsanyi J, Barabassy A, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW (2017) Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 389:1103\u20131113","journal-title":"Lancet"},{"key":"5133_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","volume":"131","author":"RE Nielsen","year":"2015","unstructured":"Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131:185\u2013196","journal-title":"Acta Psychiatr Scand"},{"key":"5133_CR51","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/gps.4399","volume":"31","author":"A O'Brien","year":"2016","unstructured":"O'Brien A (2016) Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry 31:683\u2013693","journal-title":"Int J Geriatr Psychiatry"},{"key":"5133_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","volume":"205","author":"M Penttila","year":"2014","unstructured":"Penttila M, Jaaskelainen E, Hirvonen N, Isohanni M, Miettunen J (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry J Ment Sci 205:88\u201394","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"5133_CR53","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP (2014) Evaluating the quality of evidence from a network meta-analysis. PLoS One 9:e99682","journal-title":"PLoS One"},{"key":"5133_CR54","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","volume":"172","author":"MT Samara","year":"2015","unstructured":"Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Moller HJ, Pelayo-Teran JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617\u2013629","journal-title":"Am J Psychiatry"},{"key":"5133_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajp.2013.11.017","volume":"8","author":"E Sharma","year":"2014","unstructured":"Sharma E, Rao NP, Venkatasubramanian G (2014) Association between antipsychotic-induced metabolic side-effects and clinical improvement: a review on the evidence for \u201cmetabolic threshold\u201d. Asian J Psychiatr 8:12\u201321","journal-title":"Asian J Psychiatr"},{"key":"5133_CR56","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1176\/ajp.135.7.884-a","volume":"135","author":"RC Smith","year":"1978","unstructured":"Smith RC, Strizich M, Klass D (1978) Drug history and tardive dyskinesia. Am J Psychiatry 135:1402\u20131403","journal-title":"Am J Psychiatry"},{"key":"5133_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S1461145705005110","volume":"8","author":"R Smith","year":"2005","unstructured":"Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 8:183\u2013194","journal-title":"Int J Neuropsychopharmacol"},{"key":"5133_CR58","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","volume":"192","author":"M Smith","year":"2008","unstructured":"Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry J Ment Sci 192:406\u2013411","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"5133_CR59","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","volume":"38","author":"IE Sommer","year":"2012","unstructured":"Sommer IE, Begemann MJ, Temmerman A, Leucht S (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003\u20131011","journal-title":"Schizophr Bull"},{"key":"5133_CR60","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4088\/JCP.v68n0308","volume":"68","author":"RD Spurling","year":"2007","unstructured":"Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W (2007) Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 68:406\u2013409","journal-title":"J Clin Psychiatry"},{"key":"5133_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2010.08040484","volume":"168","author":"BL Strom","year":"2011","unstructured":"Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM (2011) Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 168:193\u2013201","journal-title":"Am J Psychiatry"},{"key":"5133_CR62","first-page":"862","volume":"43","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G (2017a) Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull 43:862\u2013871","journal-title":"Schizophr Bull"},{"key":"5133_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/JCP.0000000000000662","volume":"37","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Thiyanavadivel S, Fervaha G, Remington G (2017b) Neurocognitive benefits of second-generation antipsychotics versus placebo: insufficient evidence based on a systematic review. J Clin Psychopharmacol 37:274\u2013276","journal-title":"J Clin Psychopharmacol"},{"key":"5133_CR64","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1192\/bjp.bp.114.150623","volume":"207","author":"LR Valmaggia","year":"2015","unstructured":"Valmaggia LR, Byrne M, Day F, Broome MR, Johns L, Howes O, Power P, Badger S, Fusar-Poli P, McGuire PK (2015) Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. Br J Psychiatry J Ment Sci 207:130\u2013134","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"5133_CR65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","volume":"15","author":"D Vancampfort","year":"2016","unstructured":"Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B (2016) Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 15:166\u2013174","journal-title":"World Psychiatry"},{"key":"5133_CR66","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2147\/NDT.S80925","volume":"11","author":"RA Wani","year":"2015","unstructured":"Wani RA, Dar MA, Chandel RK, Rather YH, Haq I, Hussain A, Malla AA (2015) Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat 11:685\u2013693","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5133_CR67","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/pds.1781","volume":"18","author":"MU Yood","year":"2009","unstructured":"Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L'Italien G (2009) The incidence of diabetes in atypical antipsychotic users differs according to agent\u2014results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18:791\u2013799","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5133_CR68","first-page":"339","volume":"26","author":"S Zhang","year":"2014","unstructured":"Zhang S, Lan G (2014) Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia. Shanghai Arch Psychiatry 26:339\u2013346","journal-title":"Shanghai Arch Psychiatry"},{"key":"5133_CR69","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","volume":"4","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, Li C, Davis JM, Leucht S (2017a) Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4:694\u2013705","journal-title":"Lancet Psychiatry"},{"key":"5133_CR70","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","volume":"27","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Li C, Huhn M, Rothe P, Krause M, Bighelli I, Schneider-Thoma J, Leucht S (2017b) How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 27:835\u2013844","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5133-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-018-5133-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5133-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T19:05:49Z","timestamp":1575054349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-018-5133-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["5133"],"URL":"https:\/\/doi.org\/10.1007\/s00213-018-5133-z","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}